Research Analysts Set Expectations for GPCR FY2026 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) – Research analysts at HC Wainwright lowered their FY2026 earnings estimates for shares of Structure Therapeutics in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst A. Ghosh now expects that the company will earn ($2.18) per share for the year, down from their previous forecast of ($1.84). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($2.10) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q4 2026 earnings at ($0.68) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.63) EPS, FY2027 earnings at ($2.40) EPS, FY2028 earnings at ($2.70) EPS, FY2029 earnings at ($2.79) EPS and FY2030 earnings at ($2.54) EPS.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15).

Several other equities analysts have also weighed in on the company. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Citizens Jmp reiterated a “market outperform” rating and set a $110.00 price target on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research note on Friday, August 7th. Weiss Ratings raised Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Finally, Wall Street Zen lowered Structure Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.91.

Check Out Our Latest Stock Report on GPCR

Structure Therapeutics Price Performance

Structure Therapeutics stock opened at $18.57 on Monday. Structure Therapeutics has a one year low of $18.38 and a one year high of $94.90. The company’s fifty day moving average price is $27.31 and its two-hundred day moving average price is $45.70.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. IFP Advisors Inc bought a new stake in shares of Structure Therapeutics during the 2nd quarter worth $46,000. Sterling Capital Management LLC grew its stake in Structure Therapeutics by 63.6% in the 3rd quarter. Sterling Capital Management LLC now owns 3,345 shares of the company’s stock valued at $105,000 after buying an additional 1,300 shares during the last quarter. Assetmark Inc. grew its stake in Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after buying an additional 449 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Structure Therapeutics in the 3rd quarter valued at $132,000. Finally, Parallel Advisors LLC raised its holdings in Structure Therapeutics by 12.7% in the 3rd quarter. Parallel Advisors LLC now owns 8,286 shares of the company’s stock worth $259,000 after acquiring an additional 934 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Key Structure Therapeutics News

Investors following GPCR have been watching these news items:

  • Neutral Sentiment: HC Wainwright kept its Buy rating on GPCR, offering a counterpoint to its weaker earnings outlook. HC Wainwright Has Negative Opinion of GPCR FY2026 Earnings
  • Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $2.18 from a loss of $1.84, and its Q4 2026 estimate to a loss of $0.68 from $0.50. The deeper projected losses may weigh on sentiment, especially as GPCR’s current-year results have also missed consensus expectations. HC Wainwright earnings estimates
  • Negative Sentiment: The firm’s forecasts point to continued losses in 2027–2030, including projected losses of $2.40 per share in 2027 and $2.70 in 2028. This outlook underscores the company’s ongoing earnings risk. Analysts Offer Predictions for GPCR Q1 Earnings

About Structure Therapeutics

(Get Free Report)

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

Read More

Earnings History and Estimates for Structure Therapeutics (NASDAQ:GPCR)

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.